Study of the diagnosis and treatment of cancer located in the head and neck and correlation with expression of prognostic markers

Romanian Journal of Morphology and Embryology

Volumn 54, Issue 3, 2013, Pages 487-497

  Badulescu F L ^a   Bǎdulescu, Adriana ^b   Crişan, Anda ^a   Carmen Popescu, Florina ^c  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^b TITU MAIORESCU UNIVERSITY   (Romania)

^c EMERGENCY COUNTY HOSPITAL   (Romania)

Author keywords

Head and neck cancer; Molecular markers; Prognostic; Treatment

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HEAD AND NECK TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SQUAMOUS CELL CARCINOMA; YOUNG ADULT;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84884553326     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Parkin DM, Pisani P, Ferlay J, Estimates of the worldwide incidence of 25 major cancers in 1990, Int J Cancer, 1999, 80(6):827-841.
2. Mignogna MD, Fedele S, Lo Russo L, The World Cancer Report and the burden of oral cancer, Eur J Cancer Prev, 2004, 13(2):139-142.
3. Piccirillo JF, Importance of comorbidity in head and neck cancer, Laryngoscope, 2000, 110(4):593-602.
4. Piccirillo JF, Impact of comorbidity and symptoms on the prognosis of patients with oral carcinoma, Arch Otolaryngol Head Neck Surg, 2000, 126(9):1086-1088.
5. Jensen OM, Estève J, Møller H, Renard H, Cancer in the European Community and its member states, Eur J Cancer, 1990, 26(11-12):1167-1256.
6. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Störkel S, Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections, J Histochem Cytochem, 2004, 52(7):893-901.
7. Ford AC, Grandis JR, Targeting epidermal growth factor receptor in head and neck cancer, Head Neck, 2003, 25(1): 67-73.
8. Modjtahedi H, Moscatello DK, Box G, Green M, Shotton C, Lamb DJ, Reynolds LJ, Wong AJ, Dean C, Thomas H, Eccles S, Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy, Int J Cancer, 2003, 105(2):273-280.
9. Mielcarek-Kuchta D, Olofsson J, Golusinski W, p53, Ki67 and cyclin D1 as prognostic factors of lymph node metastases in laryngeal carcinoma, Eur Arch Otorhinolaryngol, 2003, 260(10):549-554.
10. Jeannon JP, Soames J, Lunec J, Awwad S, Ashton V, Wilson JA, Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer, Clin Otolaryngol Allied Sci, 2000, 25(1):23-27.
11. Alsner J, Sørensen SB, Overgaard J, TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck, Radiother Oncol, 2001, 59(2):179-185.
12. Pignon JP, Bourhis J, Domenge C, Designé L, Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer, Lancet, 2000, 355(9208):949-955.
13. Posner MR, Colevas AD, Tishler RB, The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck, Semin Oncol, 2000, 27(4 Suppl 8): 13-24.
14. Ghi MG, Paccagnella A, D'Amanzo P, Mione CA, Fasan S, Paro S, Mastromauro C, Carnuccio R, Turcato G, Gatti C, Pallini A, Nascimben O, Biason R, Oniga F, Medici M, Rossi F, Fila G, Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study, Int J Radiat Oncol Biol Phys, 2004, 59(2):481-487.
15. Kumar S, Datta NR, Ahuja RC, Mali HR, Agarwal GN, Ayyagari S, Feasibility of non-cisplatin-based induction chemotherapy and concurrent chemoradiotherapy in advanced head and neck cancer, Acta Oncol, 1996, 35(6):721-725.
16. Hoppe F, Preisler V, Pfreundner L, Flentje M, Neoadjuvant chemotherapy and radiotherapy in laryngeal cancer - First results of a randomized study, Proc Am Soc Clin Oncol, 2001, 20:200b.
17. Adelstein DJ, Saxton JP, Lavertu P, Rybicki LA, Esclamado RM, Wood BG, Strome M, Carroll MA, Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy, J Clin Oncol, 2002, 20(5):1405-1410.
18. Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E, Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck, J Clin Oncol, 2004, 22(14):2856-2864.
19. Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D, Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02, J Clin Oncol, 2010, 28(18):2996-3001.
20. Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, Eliachar I, Strome M, Larto MA, Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck, Cancer, 2000, 88(4):876-883.
21. Etessami A, Lapeyre M, Tortochaux J, Geoffrois L, Verrelle P, Domenge C, Wibault P, Auperin A, Bourhis J, Very accelerated RT versus accelerated RT + concomitant CDDP-5FU in patients with palpable N2 and N3 HNSCC: preliminary results of the GORTEC 96-01 randomized trial, Lung Cancer, 2001, 34(Suppl 1):S68.
22. Pinnarò P, Cercato MC, Giannarelli D, Carlini P, Del Vecchio MR, Impiombato FA, Marzetti F, Milella M, Cognetti F, A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck, Ann Oncol, 1994, 5(6):513-519.
23. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA; Eastern Cooperative Oncology Group, Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group, J Clin Oncol, 2005, 23(15): 3562-3567.
24. Abitbol A, Abdel-Wahab M, Lewin A, Troner M, Rodrigues MA, Hamilton-Nelson KL, Markoe A, Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluoro-uracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol, Int J Radiat Oncol Biol Phys, 2002, 53(4):942-947.
25. Hainsworth JD, Meluch AA, McClurkan S, Gray JR, Stroup SL, Burris HA 3rd, Yardley DA, Bradof JE, Yost K, Ellis JK, Greco FA, Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network, Cancer J, 2002, 8(4):311-321.
26. Rapidis AD, Trichas M, Stavrinidis E, Roupakia A, Ioannidou G, Kritselis G, Liossi P, Giannakouras G, Douzinas EE, Katsilieris I, Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up, Oral Oncol, 2006, 42(7):675-684.
27. Vermorken JB, Remenar E., van Herpen C, Germa Lluch J, Stewart S, Gorlia T, Degardin M, Schollen K, Bernier J, Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for non-resectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971), ASCO Annual Meeting Proceedings (Post-Meeting Edition), J Clin Oncol, 2004, 22(14S):5508.
28. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ, Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm, J Clin Oncol, 2006, 24(7):1072-1078.
29. Bonner JA, Harari PM, Giralt J, Azarnia N, Cohen RB, Raben D, Jones C, Kies MS, Baselga J, Ang KK, Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab, J Clin Oncol, 2004, 22(14S):5507.
30. Posner MR, Wirth LJ, Cetuximab and radiotherapy for head and neck cancer, N Engl J Med, 2006, 354(6):634-636.
31. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med, 2006, 354(6):567-578.